Literature DB >> 3046514

IgG antibodies to Aspergillus fumigatus in cystic fibrosis: a laboratory correlate of disease activity.

K D Forsyth1, A W Hohmann, A J Martin, J Bradley.   

Abstract

Serum was collected from 50 patients with cystic fibrosis, and IgG antibodies to Aspergillus fumigatus were measured by enzyme linked immunosorbent assay (ELISA). In addition, total IgE and Aspergillus specific IgE antibodies were measured in 41 of the 50. A close association was found between pulmonary function and clinical state, and IgG antibodies to Aspergillus. There was no association between pulmonary function or clinical state and IgE antibodies. It is postulated that in patients with cystic fibrosis, Aspergillus fumigatus may contribute to deterioration in pulmonary function by local pathogenicity, or by hypersensitivity mechanisms mediated by IgG.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3046514      PMCID: PMC1778949          DOI: 10.1136/adc.63.8.953

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  18 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  Immune response of the human respiratory tract. I. Immunoglobulin levels and influenza virus vaccine antibody response.

Authors:  R H Waldman; P F Jurgensen; G N Olsen; R Ganguly; J E Johnson
Journal:  J Immunol       Date:  1973-07       Impact factor: 5.422

3.  Serum precipitins to Aspergillus fumigatus in cystic fibrosis.

Authors:  R H Schwartz; D E Johnstone; D S Holsclaw; R R Dooley
Journal:  Am J Dis Child       Date:  1970-11

4.  Immunological studies in cystic fibrosis.

Authors:  M W Turner; J O Warner; C R Stokes
Journal:  Arch Dis Child       Date:  1978-08       Impact factor: 3.791

5.  Pseudomonas aeruginosa infection in cystic fibrosis. Occurrence of precipitating antibodies against pseudomonas aeruginosa in relation to the concentration of sixteen serum proteins and the clinical and radiographical status of the lungs.

Authors:  N Hoiby; L Jacobsen; B A Jorgensen; E Lykkegaard; B Weeke
Journal:  Acta Paediatr Scand       Date:  1974-11

6.  Cell-mediated immunity in patients with cystic fibrosis.

Authors:  A Gibbons; J D Allan; A Holzel; H McFarlane
Journal:  Br Med J       Date:  1976-01-17

7.  Incidence of serum antibodies to several Aspergillus species and to Candida albicans in cystic fibrosis.

Authors:  S P Galant; R W Rucker; C E Groncy; I D Wells; H S Novey
Journal:  Am Rev Respir Dis       Date:  1976-08

8.  Pseudomonas aeruginosa: immune status in patients with cystic fibrosis.

Authors:  R G Doggett; G M Harrison
Journal:  Infect Immun       Date:  1972-10       Impact factor: 3.441

9.  Hypogammaglobulinemia in patients with cystic fibrosis.

Authors:  W J Matthews; M Williams; B Oliphint; R Geha; H R Colten
Journal:  N Engl J Med       Date:  1980-01-31       Impact factor: 91.245

10.  Aspergillosis and atopy in cystic fibrosis.

Authors:  L A Nelson; M L Callerame; R H Schwartz
Journal:  Am Rev Respir Dis       Date:  1979-10
View more
  11 in total

Review 1.  Cystic fibrosis, pathophysiological and clinical aspects.

Authors:  H J Neijens; M Sinaasappel; R de Groot; J C de Jongste; S E Overbeek
Journal:  Eur J Pediatr       Date:  1990-08       Impact factor: 3.183

2.  IgG antibodies to Aspergillus fumigatus in cystic fibrosis.

Authors:  C Vazquez; N Aramburu; A Sojo; J C Vitoria; C Pascual
Journal:  Arch Dis Child       Date:  1989-07       Impact factor: 3.791

3.  Specific IgG subclass antibody pattern to Aspergillus fumigatus in patients with cystic fibrosis with allergic bronchopulmonary aspergillosis (ABPA).

Authors:  M Skov; T Pressler; H E Jensen; N Høiby; C Koch
Journal:  Thorax       Date:  1999-01       Impact factor: 9.139

4.  Cystic fibrosis and allergic bronchopulmonary aspergillosis.

Authors:  E J Simmonds; J M Littlewood; E G Evans
Journal:  Arch Dis Child       Date:  1990-05       Impact factor: 3.791

5.  Aspergillus fumigatus colonisation and population density of place of residence in cystic fibrosis.

Authors:  E J Simmonds; J M Littlewood; V Hopwood; E G Evans
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

6.  Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center.

Authors:  David A Stevens; Richard B Moss; Cathy Hernandez; Karl V Clemons; Marife Martinez
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

7.  Studies of Pseudomonas aeruginosa Mutants Indicate Pyoverdine as the Central Factor in Inhibition of Aspergillus fumigatus Biofilm.

Authors:  Gabriele Sass; Hasan Nazik; John Penner; Hemi Shah; Shajia Rahman Ansari; Karl V Clemons; Marie-Christine Groleau; Anna-Maria Dietl; Paolo Visca; Hubertus Haas; Eric Déziel; David A Stevens
Journal:  J Bacteriol       Date:  2017-12-05       Impact factor: 3.490

8.  Interaction between Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis.

Authors:  Jingming Zhao; Wencheng Yu
Journal:  PeerJ       Date:  2018-11-09       Impact factor: 2.984

9.  Intermicrobial interaction: Aspergillus fumigatus siderophores protect against competition by Pseudomonas aeruginosa.

Authors:  Gabriele Sass; Shajia R Ansari; Anna-Maria Dietl; Eric Déziel; Hubertus Haas; David A Stevens
Journal:  PLoS One       Date:  2019-05-08       Impact factor: 3.752

10.  Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium.

Authors:  Jose A G Ferreira; John C Penner; Richard B Moss; Janus A J Haagensen; Karl V Clemons; Alfred M Spormann; Hasan Nazik; Kevin Cohen; Niaz Banaei; Elisabete Carolino; David A Stevens
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.